NCT03816839View on ClinicalTrials.gov

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

October 27, 2020

Study Completion Date

December 26, 2024

Conditions
Breast Cancer
Interventions
DRUG

Amcenestrant (SAR439859)

"Pharmaceutical form: Capsules~Route of administration: Oral"

Trial Locations (3)

464-8681

Investigational Site Number : 3920003, Nagoya

277-8577

Investigational Site Number : 3920001, Kashiwa-shi

104-0045

Investigational Site Number : 3920002, Chuo-ku

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03816839 - Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2) | Biotech Hunter | Biotech Hunter